Symbols

ABSI

Absci·NASDAQ

--(--)

ABSI Profile

Absci Corporation

A drug and target discovery company that harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins

Industry

Biological Technology

Established Date

Listing Date

07/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

140

Fiscal Year Ends

12-31

Website

www.absci.com

Security Type

Common stock

Office address

18105 SE Mill Plain Blvd, Vancouver, WA 98683

Business

Introduction

Absci Corporation was incorporated as a limited liability company in Oregon in August 2011. The company is a clinical-stage biopharmaceutical company that develops differentiated antibody therapies using artificial intelligence native methods. Its lead drug candidate, ABS-201, is an anti-prolactin receptor antibody that is being developed for androgenic alopecia and endometriosis, and related clinical trials are ongoing and planned.